Concepedia

Publication | Open Access

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4<sup>+</sup>T-lymphocyte counts

DOIFull Paper Access

69

Citations

20

References

2018

Year

Daniela A. Bota, Jinah Chung, Manisha Dandekar, Jose Carrillo, Xiao–Tang Kong, Beverly Fu, Frank P. K. Hsu, Axel H. Schönthal, Florence M. Hofman, Thomas C. Chen,
CNS Oncology

Abstract

The addition of ERC1671/GM-CSF/cyclophosphamide to bevacizumab resulted in a clinically meaningful survival benefit with minimal additional toxicity.

References

YearCitations

Page 1